Journal article
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes
Haematologica (Roma), Vol.108(11), pp.3025-3032
11/2023
DOI: 10.3324/haematol.2023.282780
PMCID: PMC10620571
PMID: 37102592
Abstract
Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma (r/r cHL) demonstrated an improved 2-year progression free survival (PFS) over placebo. However, most patients are unable to complete all 16 cycles at full dose due to toxicity. This retrospective, multicenter study investigated the effect of cumulative maintenance BV dose on 2-year PFS. Data were collected from patients who received at least one cycle of BV maintenance after ASCT with one of the following high-risk features: primary refractory disease (PRD), extra-nodal disease (END), or relapse < 12 months (RL<12) from the end of frontline therapy. Cohort 1 had patients with > 75% of the planned total cumulative dose, cohort 2 with 51 - 75% of dose, and cohort 3 with ≤ 50% of dose. The primary outcome was 2-year PFS. A total of 118 patients were included. Fifty percent had PRD, 29% had RL<12, and 39% had END. Forty-four percent of patients had prior exposure to BV and 65% were in complete remission (CR) before ASCT. Only 14% of patients received the full planned BV dose. Sixty-one percent of patients discontinued maintenance early and majority of those (72%) were due to toxicity. The 2-year PFS for the entire population was 80.7%. The 2-year PFS was 89.2% for cohort 1 (n=39), 86.2% for cohort 2 (n=33), and 77.9% for cohort 3 (n=46) (p = 0.70). These data are reassuring for patients who require dose reductions or discontinuation to manage toxicity.
Details
- Title: Subtitle
- Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes
- Creators
- Charlotte B Wagner - University of UtahKen Boucher - University of UtahAdrienne Nedved - Mayo ClinicIvana N Micallef - Mayo ClinicSanjal Desai - University of MinnesotaHaris Hatic - University of AlabamaGaurav Goyal - University of AlabamaErin Zacholski - Virginia Commonwealth UniversityAmanda Fegley - Virginia Commonwealth UniversityAudrey M Sigmund - The Ohio State UniversityDavid A Bond - The Ohio State UniversityCourtney Samuels - University of Colorado Cancer CenterManali K Kamdar - University of Colorado Cancer CenterSheeba Ba Aqeel - Roswell Park Comprehensive Cancer CenterPallawi Torka - Roswell Park Comprehensive Cancer CenterKira MacDougall - University of Oklahoma Health Sciences CenterAzra Borogovac - University of Oklahoma Health Sciences CenterSridevi Rajeeve - Mount Saint Vincent UniversitySuchitra Sundaram - Mount Saint Vincent UniversityKalub Fedak - The Barbara Ann Karmanos Cancer InstituteDipenkumar Modi - The Barbara Ann Karmanos Cancer InstituteElizabeth Travers - University of Kentucky HealthCareSabarish Ayyappan - University of IowaNitin Chilakamarri - University of California, IrvineElizabeth A Brem - University of California, IrvineDaniel A Ermann - University of UtahLindsey A Fitzgerald - University of UtahBoyu Hu - University of UtahDeborah M Stephens - University of UtahHarsh Shah - University of Utah
- Resource Type
- Journal article
- Publication Details
- Haematologica (Roma), Vol.108(11), pp.3025-3032
- DOI
- 10.3324/haematol.2023.282780
- PMID
- 37102592
- PMCID
- PMC10620571
- NLM abbreviation
- Haematologica
- ISSN
- 0390-6078
- eISSN
- 1592-8721
- Language
- English
- Electronic publication date
- 04/27/2023
- Date published
- 11/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984399639602771
Metrics
11 Record Views